Progyny, Inc. PGNY
36.43 USD +0.48 (+1.34%)
At closeNov 10, 2026, 5:21 PM EST
36.20 -0.23 -0.63%
After hours · Nov 10, 5:21 PM ET
35.00 Day range 36.45
16.10 52-week range 36.45
- YTD
- +41.86%
- 1 year
- +54.23%
News
benzinga.com JP Morgan Maintains Neutral on Progyny, Raises Price Target to $35 JP Morgan analyst Lisa Gill maintains Progyny (NASDAQ:PGNY) with a Neutral and raises the price target from $30 to $35.
defenseworld.net Progyny (NASDAQ:PGNY) Reaches New 12-Month High After Earnings Beat Shares of Progyny, Inc. (NASDAQ: PGNY - Get Free Report) reached a new 52-week high during mid-day trading on Thursday after the company announced better than expected quarterly earnings. The company…
benzinga.com Leerink Partners Maintains Outperform on Progyny, Raises Price Target to $38 Leerink Partners analyst Michael Cherny maintains Progyny (NASDAQ:PGNY) with a Outperform and raises the price target from $37 to $38.
benzinga.com Wells Fargo Maintains Overweight on Progyny, Raises Price Target to $38 Wells Fargo analyst Stan Berenshteyn maintains Progyny (NASDAQ:PGNY) with a Overweight and raises the price target from $37 to $38.
benzinga.com Citizens Maintains Market Outperform on Progyny, Raises Price Target to $38 Citizens analyst Constantine Davides maintains Progyny (NASDAQ:PGNY) with a Market Outperform and raises the price target from $33 to $38.
benzinga.com Cantor Fitzgerald Maintains Overweight on Progyny, Raises Price Target to $35 Cantor Fitzgerald analyst Sarah James maintains Progyny (NASDAQ:PGNY) with a Overweight and raises the price target from $31 to $35.
marketbeat.com Progyny Q3 Earnings Call Highlights Progyny NASDAQ: PGNY raised the midpoint of its full-year 2026 guidance after reporting record third-quarter revenue and profitability and securing a record 1.3 million new covered lives during its…
seekingalpha.com Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript
zacks.com Progyny (PGNY) Tops Q3 Earnings and Revenue Estimates Progyny (PGNY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.45 per share a year ago.
benzinga.com Progyny Q3 2026 Earnings Call Transcript Progyny (NASDAQ:PGNY) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com Progyny Sees Q4 Adj EPS $0.53-$0.58 vs $0.34 Est; Sees Sales $344.700M-$364.700M vs $353.596M Est Progyny (NASDAQ:PGNY) is looking for Q4 Adj EPS of $0.53-$0.58 vs $0.34 analyst estimate. sees sales of $344.700 million-$364.700 million vs $353.596 million analyst estimate.
- benzinga.com Progyny Raises FY2026 Adj EPS Guidance from $2.04-$2.10 to $2.09-$2.13 vs $1.28 Est; Raises FY2026 Sales Guidance from $1.360B-$1.385B to $1.365B-$1.385B vs $1.373B Est Progyny (NASDAQ:PGNY) raises FY2026 Adj EPS guidance from $2.04-$2.10 to $2.09-$2.13 vs $1.28 analyst estimate. Raises FY2026 sales outlook from $1.360 billion-$1.385 billion to $1.365 billion-$1.385…
globenewswire.com Progyny, Inc. Announces Third Quarter 2026 Results Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA and Net IncomeSelling Season Yields Record 1.3 Million New Covered Lives with Another Year of Near 100% Retention…- benzinga.com Citizens Maintains Market Outperform on Progyny, Raises Price Target to $33 Citizens analyst Constantine Davides maintains Progyny (NASDAQ:PGNY) with a Market Outperform and raises the price target from $31 to $33.
benzinga.com JP Morgan Maintains Neutral on Progyny, Raises Price Target to $30 JP Morgan analyst Lisa Gill maintains Progyny (NASDAQ:PGNY) with a Neutral and raises the price target from $27 to $30.- benzinga.com Wells Fargo Initiates Coverage On Progyny with Overweight Rating, Announces Price Target of $37 Wells Fargo analyst Stan Berenshteyn initiates coverage on Progyny (NASDAQ:PGNY) with a Overweight rating and announces Price Target of $37.
benzinga.com Truist Securities Maintains Buy on Progyny, Raises Price Target to $36 Truist Securities analyst Jailendra Singh maintains Progyny (NASDAQ:PGNY) with a Buy and raises the price target from $33 to $36.- benzinga.com Barclays Maintains Equal-Weight on Progyny, Lowers Price Target to $30 Barclays analyst Peter Warendorf maintains Progyny (NASDAQ:PGNY) with a Equal-Weight and lowers the price target from $34 to $30.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The market value of their outstanding shares is at $3.7 billion. As per the news, the Q1 earnings report…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 billion. The company's, Q1 earnings…- benzinga.com Progyny Sees Q3 Adj EPS $0.50-$0.52 vs $0.33 Est; Sees Sales $335.000M-$345.000M vs $350.185M Est Progyny (NASDAQ:PGNY) is looking for Q3 Adj EPS of $0.50-$0.52 vs $0.33 analyst estimate. sees sales of $335.000 million-$345.000 million vs $350.185 million analyst estimate.
- benzinga.com Progyny Raises FY2026 Adj EPS Guidance from $1.98-$2.09 to $2.04-$2.10 vs $1.29 Est; Lowers FY2026 Sales Guidance from $1.365B-$1.405B to $1.360B-$1.385B vs $1.384B Est Progyny (NASDAQ:PGNY) raises FY2026 Adj EPS guidance from $1.98-$2.09 to $2.04-$2.10 vs $1.29 analyst estimate. Lowers FY2026 sales outlook from $1.365 billion-$1.405 billion to $1.360 billion-$1.385…
benzinga.com Progyny Q2 Adj. EPS $0.55 Beats $0.34 Estimate, Sales $350.511M Beat $348.682M Estimate Progyny (NASDAQ:PGNY) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.34 by 61.76 percent. This is a 14.58 percent increase over earnings of $0.48 per…
benzinga.com This Clorox Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Wall Street analysts change outlook on top stocks. See upgrade, downgrade, and initiation changes on our analyst ratings page. CLX stock has mixed reviews.
benzinga.com Barclays Downgrades Progyny to Equal-Weight, Raises Price Target to $34 Barclays analyst Peter Warendorf downgrades Progyny (NASDAQ:PGNY) from Overweight to Equal-Weight and raises the price target from $27 to $34.- benzinga.com BTIG Maintains Buy on Progyny, Raises Price Target to $40 BTIG analyst David Larsen maintains Progyny (NASDAQ:PGNY) with a Buy and raises the price target from $30 to $40.
- benzinga.com Canaccord Genuity Maintains Buy on Progyny, Raises Price Target to $36 Canaccord Genuity analyst Richard Close maintains Progyny (NASDAQ:PGNY) with a Buy and raises the price target from $30 to $36.
benzinga.com Top 3 Health Care Stocks That May Implode This Month Warning: RSI is above 70 for 3 overbought stocks in healthcare. Progyny, 10X Genomics, and Privia Health have high RSI values and strong price action.- benzinga.com Keybanc Maintains Overweight on Progyny, Raises Price Target to $35 Keybanc analyst Scott Schoenhaus maintains Progyny (NASDAQ:PGNY) with a Overweight and raises the price target from $30 to $35.
- benzinga.com Truist Securities Maintains Buy on Progyny, Raises Price Target to $33 Truist Securities analyst Jailendra Singh maintains Progyny (NASDAQ:PGNY) with a Buy and raises the price target from $30 to $33.
- benzinga.com B of A Securities Maintains Buy on Progyny, Raises Price Target to $31 B of A Securities analyst Michael Cherny maintains Progyny (NASDAQ:PGNY) with a Buy and raises the price target from $29 to $31.
benzinga.com This Stubhub Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. See what other analysts think of these stocks.- benzinga.com Canaccord Genuity Upgrades Progyny to Buy, Raises Price Target to $30 Canaccord Genuity analyst Richard Close upgrades Progyny (NASDAQ:PGNY) from Hold to Buy and raises the price target from $19 to $30.
- benzinga.com Barclays Maintains Overweight on Progyny, Raises Price Target to $27 Barclays analyst Glen Santangelo maintains Progyny (NASDAQ:PGNY) with a Overweight and raises the price target from $23 to $27.
benzinga.com Truist Securities Maintains Buy on Progyny, Raises Price Target to $30 Truist Securities analyst Jailendra Singh maintains Progyny (NASDAQ:PGNY) with a Buy and raises the price target from $28 to $30.- benzinga.com Citizens Maintains Market Outperform on Progyny, Raises Price Target to $31 Citizens analyst Constantine Davides maintains Progyny (NASDAQ:PGNY) with a Market Outperform and raises the price target from $30 to $31.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Progyny Sees Q2 Adj EPS $0.50-$0.53 vs $0.33 Est; Sees Sales $342.000M-$355.000M vs $347.385M Est Progyny (NASDAQ:PGNY) is looking for Q2 Adj EPS of $0.50-$0.53 vs $0.33 analyst estimate. sees sales of $342.000 million-$355.000 million vs $347.385 million analyst estimate.
- benzinga.com Progyny Raises FY2026 Adj EPS Guidance from $1.83-$1.95 to $1.98-$2.09 vs $1.32 Est; Raises FY2026 Sales Guidance from $1.355B-$1.405B to $1.365B-$1.405B vs $1.376B Est Progyny (NASDAQ:PGNY) raises FY2026 Adj EPS guidance from $1.83-$1.95 to $1.98-$2.09 vs $1.32 analyst estimate. Raises FY2026 sales outlook from $1.355 billion-$1.405 billion to $1.365 billion-$1.405…
- benzinga.com Progyny Q1 Adj. EPS $0.50 Beats $0.30 Estimate, Sales $328.504M Beat $326.514M Estimate Progyny (NASDAQ:PGNY) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.30 by 66.67 percent. This is a 4.17 percent increase over earnings of $0.48 per…
- benzinga.com Progyny Launches Progyny Select, The Industry's First Fully Insured, Comprehensive Supplemental Fertility And Family Building Plan Available in the U.S., Progyny Select enables small employers to have access to fertility solutions in a fixed premium model. As the rate of infertility continues to rise and national attention on…
- benzinga.com Barclays Maintains Overweight on Progyny, Lowers Price Target to $23 Barclays analyst Glen Santangelo maintains Progyny (NASDAQ:PGNY) with a Overweight and lowers the price target from $29 to $23.
- benzinga.com Progyny Announces Settlement Of Derivative Lawsuit Over Historical Non-Employee Director Compensation On March 13, 2026, Progyny, Inc. (the "Company") issued a Notice of Pendency of Settlement of Derivative Action, which is attached hereto as Exhibit 99.1, in accordance with the terms of a settlement…
- benzinga.com Canaccord Genuity Maintains Hold on Progyny, Lowers Price Target to $19 Canaccord Genuity analyst Richard Close maintains Progyny (NASDAQ:PGNY) with a Hold and lowers the price target from $26 to $19.
- benzinga.com Keybanc Maintains Overweight on Progyny, Lowers Price Target to $28 Keybanc analyst Scott Schoenhaus maintains Progyny (NASDAQ:PGNY) with a Overweight and lowers the price target from $32 to $28.
- benzinga.com Truist Securities Maintains Buy on Progyny, Lowers Price Target to $28 Truist Securities analyst Jailendra Singh maintains Progyny (NASDAQ:PGNY) with a Buy and lowers the price target from $34 to $28.
benzinga.com Flutter Entertainment Posts Downbeat Q4 Results, Joins Zscaler, Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session (CORRECTED) - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Progyny Sees Q1 Adj EPS $0.42-$0.45 vs $0.39 Est; Sees Sales $319.000M-$332.000M vs $344.896M Est Progyny (NASDAQ:PGNY) is looking for Q1 Adj EPS of $0.42-$0.45 vs $0.39 analyst estimate. sees sales of $319.000 million-$332.000 million vs $344.896 million analyst estimate.